02:41 PM EDT, 03/26/2024 (MT Newswires) -- Verrica Pharmaceuticals ( VRCA ) said Tuesday its lead product, Ycanth, has received New Chemical Entity status and a listing in the Orange Book from the US Food and Drug Administration.

"While NCE status will provide Ycanth with a minimum of five years of protection, we anticipate our full patent portfolio to provide protection from generic competition for the next decade and potentially beyond," Chief Executive Ted White said.

Ycanth is a topical solution to treat molluscum contagiosum in adults and children 2 years of age and older, the firm said. Formally described as the Approved Drug Products with Therapeutic Equivalence Evaluations, the Orange Book is a FDA publication that provides a list of drugs approved as safe and effective.

Shares of the company climbed over 5% in recent trading.

Price: 5.33, Change: +0.26, Percent Change: +5.24